Rick Simpson Oil (RSO) in Northern Europe: The Complete Guide by OilWell Cannabis

If you’re reading this in Stockholm, Oslo, Copenhagen, Helsinki, Reykjavik, Tallinn, Riga, or Vilnius — or anywhere across the Nordic and Baltic regions — you’ve likely encountered the term “RSO” in online forums, patient support groups, or perhaps through American cannabis culture. Maybe you’re a cancer patient exploring integrative options. Maybe you’re a chronic pain sufferer exhausted by the long wait times in our universal healthcare systems. Maybe you’re a veteran from a NATO deployment dealing with PTSD, or someone tapering off benzodiazepines after discovering how easily they’re prescribed in Northern Europe. Whoever you are, you deserve honest, evidence-based answers about what Rick Simpson Oil actually is — and what it isn’t.

We’re OilWell Cannabis, a Houston-based company with deep roots in medical-grade formulation and a decade-long journey that began with a paralyzed dog named Bentley. We’ve shipped our RSO products to customers across six continents, including throughout Northern Europe. We publish our complete formulas publicly because we believe accessibility matters more than gatekeeping. This guide is written specifically for you — whether you’re in Norway’s fjords, Finland’s lakelands, or Estonia’s digital-forward cities. We’ll explain the science, the legal framework, the cultural context, and exactly what makes our approach different from both traditional black-market RSO and the limited medical cannabis programs available in your region.

Who Was Rick Simpson, and Why Does His Story Matter to Northern Europe?

Rick Simpson was born in 1949 in Amherst, Nova Scotia — about as far from Northern Europe as you can get geographically, yet his story resonates across our shared healthcare frustrations. He wasn’t a doctor, scientist, or medical researcher. He was a power engineer and maintenance worker, a blue-collar tradesman who turned to cannabis after the medical system failed him catastrophically.

In 1997, Simpson suffered a serious head injury from a scaffolding fall at a hospital in Moncton. The aftermath — persistent tinnitus, dizziness, post-concussion symptoms — mirrors what many Northern European workers face in construction, maritime industries, and manual labor, where workplace injuries often lead to chronic conditions that our healthcare systems struggle to address long-term. The medications prescribed to Simpson either didn’t help or made things worse. When he asked his physician about cannabis, the request was refused. This pattern still plays out across Scandinavia and the Baltics today, where physicians may be hesitant to discuss cannabis even when patients are desperate for alternatives to opioids or benzodiazepines.

Simpson’s interest in concentrated cannabis oil deepened after learning about a 1974 NIH-funded study at the Medical College of Virginia, where THC reportedly slowed tumors in mice. That study — originally intended to demonstrate harm — became his foundational reference, even though its findings were never replicated in controlled human cancer trials. This is crucial for Northern European readers to understand: the 1974 study was intriguing preclinical science, not clinical proof.

The 2003 Skin Cancer Incident That Started Everything

In 2003, Simpson noticed three bumps on his arm diagnosed as basal cell carcinoma. Rather than pursue conventional treatment, he applied concentrated cannabis oil directly to the lesions, covered them with bandages, and claimed they disappeared within four days. Important context: No independent medical verification, biopsy confirmation, or clinical follow-up has ever been published in any peer-reviewed source. This is personal testimony, not medical evidence — yet it became the origin story of RSO and the catalyst for a global movement.

In Northern Europe, we’re culturally conditioned to trust institutional medicine and evidence-based protocols. We have some of the world’s best cancer registries in the Nordic countries, and our oncologists follow rigorous treatment guidelines. We understand that personal anecdotes, however compelling, cannot substitute for clinical trials. Yet we also know that institutional medicine sometimes fails individuals — that Nordic cancer patients face waiting lists for specialized care, that palliative options can feel limited, and that integrative approaches remain controversial despite patient interest. Simpson’s story resonates because it represents the ultimate patient-driven experiment: when the system couldn’t help, he tried something radical.

The Crusade: Spreading the Oil

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free — no charges, no profit. He claimed to help people with cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more. In 2005, his story reached global audiences through the documentary Run From The Cure, which became foundational in cannabis communities worldwide. The film was distributed freely online — much like how Nordic activists share health information through patient forums and social media groups when conventional channels are unavailable.

But Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police raided his property in 2005 and 2009. He was charged with cultivation, possession, and trafficking. Eventually, he left Canada for Europe, living in Croatia and the Netherlands while continuing his advocacy. This legal persecution mirrors what cannabis activists have faced across Northern Europe, where possession laws remain strict despite growing medical cannabis programs. In Sweden, cannabis possession can still lead to criminal records. In Finland, medical cannabis access is highly restricted. In Estonia, while drug policies have softened, personal cultivation remains illegal. Simpson’s experience reminds us that the path to legal access has been paved by individuals who risked everything.

What Simpson Got Right — And What He Overstated

Simpson drew global attention to cannabinoids as serious biomedical research targets when the world ignored them. He helped create the political and cultural conditions for today’s legal cannabis industry. The term “RSO” remains the most recognized name for full-spectrum cannabis extract. These contributions are historically significant.

However, his cure claims exceeded the evidence. He maintained that RSO could cure cancer and many diseases, encouraging patients to use it potentially in place of proven therapies. This is dangerous. In Northern Europe, where our healthcare systems provide universal access to oncology treatments, delaying or foregoing proven cancer therapies carries genuine harm potential. Our oncology centers — from Oslo’s Radiumhospitalet to Copenhagen’s Rigshospitalet — follow evidence-based protocols that have saved countless lives. Cannabis oil is not a substitute for these treatments.

The Traditional RSO Protocol: Understanding the 60-Gram Regimen

Simpson’s core recommendation was consuming 60 grams of concentrated oil over approximately 90 days. This protocol was designed around crude, unstandardized material with no lab verification. Here’s what it entailed:

Week 1: Start with a dose the size of half a grain of rice (10-15mg) taken three times daily. Total daily intake: 30-45mg.

Weeks 2-5: Double the dose every four days to build THC tolerance gradually. Target: reach 1 gram (1,000mg) per day by week 5.

Weeks 5-12: Maintain 1 gram per day, divided into three doses of ~333mg each, until all 60 grams are consumed.

At peak dosing, this meant consuming roughly 600-900mg of delta-9 THC daily — far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20mg per day.

Critical Context for Northern European Patients

This protocol was never validated in controlled trials. It assumes crude, unstandardized material. The doses carry serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. For cancer patients in Norway, Sweden, or Denmark — who are often medically complex — using unregulated, unstandardized cannabis oil as a primary treatment introduces risks beyond the oil itself.

Our Nordic cancer registries and integrated oncology networks provide standardized care with documented outcomes. Adding unverified substances to this regimen without medical supervision could interfere with treatment efficacy or cause harmful interactions. This is why OilWell’s approach is fundamentally different.

Traditional RSO vs. Modern Formulated RSO: What Northern European Consumers Need to Know

The table below shows why the “RSO” label on products sold in Northern Europe may mean something completely different from what Simpson made.

Our Origin Story: Why We Built OilWell Differently

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. But Colin’s story begins in McAllen, Texas — right across the river from Reynosa, Mexico. The McAllen-Reynosa Borderplex is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. Colin grew up there, exposed to violence, cartel activity, and systemic poverty. By sixteen, he’d transported items across the border. Many of his best friends were killed or imprisoned. He left home and faced every form of violence imaginable.

Despite this, Colin chose cannabis over darker paths. He learned the plant intimately in the pre-legalization world, then transitioned to legitimate business. He became a formally trained software engineer and did custom development for Baylor College of Medicine — one of America’s most prestigious medical institutions. That combination of deep plant knowledge and medical-grade technical precision defines everything we do.

But the real origin of OilWell isn’t in Houston. It begins with a dog named Bentley.

Bentley: The Dog Who Changed Everything

Bentley was more than a pet — he was family. When veterinarians told Colin that Bentley was paralyzed and facing euthanasia, that the pain medications would destroy his organs, Colin refused to accept it. A rescue worker named Jessica asked a simple question: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

That question changed everything.

Colin learned to create CBD golden paste — a specialized cannabinoid formula for pets. This wasn’t a cure, but it was hope. And that hope delivered what veterinary medicine said was impossible: Bentley got up, walked over, and brought his ball to play. From paralyzed and facing death to fetching his ball. Dogs don’t respond to placebo. This was real.

Bentley lived ten more years, dying naturally at age twenty. During those years, Colin developed specialized formulas for every age-related condition:

• Neurodegeneration → CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection
• Dementia → CBC’s role in neurogenesis
• Glaucoma → THC’s CB1 agonism for intraocular pressure
• Arthritis → Multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene

Single cannabinoids weren’t enough. Bentley’s evolving conditions required multi-cannabinoid synergy. This decade of real-world formulation testing — on a patient Colin loved more than anything — became the foundation of our RSO formula.

Our Own Struggles: PTSD and Benzo Withdrawal

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he quit Xanax cold turkey — a notoriously dangerous feat — he used the cannabinoid knowledge developed saving Bentley. Our Peace Gummies formula was created during midnight experiments while fighting through benzo withdrawal. Colin personally uses the vape form for insomnia and severe PTSD. This isn’t theoretical knowledge. He lived what many of you in Northern Europe are living: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills don’t.

Over time, we’ve developed formulas that doctors use for Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. We focus on accessibility for everyone — including vegans, diabetics, and those with specific dietary needs.

Why Our Formulas Diverge from Traditional RSO

Our RSO is not traditional Rick Simpson Oil. It’s informed by the tradition but departs from it in deliberate, evidence-motivated ways that solve the problems Simpson’s original method couldn’t address.

Multi-Cannabinoid Approach

Traditional RSO relied on whatever single strain the maker grew. Our formulas intentionally include seven cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC. The entourage-effect literature suggests potential benefit from cannabinoid diversity, though robust clinical proof of whole-formula synergy remains limited [20][29].

Terpene Preservation

Traditional RSO had essentially no terpenes due to solvent and heat destruction. We include live terpenes at 5% with a specific seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing [20][21][23][24][25][26][27][28][29].

THCa as a Separate Ingredient

Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. Our sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC [12].

Reduced Delta-9 THC Dominance

Traditional RSO was 60-90% delta-9 THC. Our formula uses delta-9 THC at only 90 mg while distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than single-compound dominance.

Product Format Innovation

Simpson envisioned only one format: oral oil from a syringe. We offer both a 30 mL sublingual oil and a 1-gram vape cartridge, each with format-specific formulations acknowledging that different delivery routes have different pharmacokinetic profiles [14].

The THCa Legal Framework: Why This Matters for Northern Europe

The 2018 U.S. Farm Bill legalized hemp products containing less than 0.3% delta-9 THC. This framework is crucial for Northern European customers because it enables legal international shipping.

Our sublingual oil contains only 90 mg of delta-9 THC in the entire 30 mL bottle — 3 mg per mL — well under the 0.3% threshold. All cannabinoids are hemp-derived. At the point of sale, the product is Farm Bill compliant and legal to ship to jurisdictions with compatible hemp laws.

The Decarboxylation Choice: Patient-Controlled Potency

THCa is the acidic, non-psychoactive precursor to delta-9 THC. Our formula preserves THCa at 1,500 mg, creating three distinct usage options:

Option 1 — Raw, No Heat: All 1,500 mg stays as THCa — completely non-psychoactive. The THCa literature describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option is compatible with work, driving, and daytime use with zero impairment — crucial for Northern European professionals who need functional relief.

Option 2 — Fully Activated, Home Decarboxylation: Heating the oil at 125°C (260°F) for 45-60 minutes converts 1,500 mg THCa into approximately 1,315 mg delta-9 THC. Combined with the existing 90 mg delta-9 THC, this yields ~1,405 mg total delta-9 THC. Combined with 6,000 mg delta-8 THC, the activated product achieves psychoactive potency comparable to traditional illegal RSO — 100% legally, because decarboxylation occurs at your discretion after purchase.

Option 3 — Vape, Auto-Decarboxylation: Our vape cartridge vaporizes at 200-230°C (400-450°F), instantly converting THCa to delta-9 THC with each inhalation. This is the fastest-onset RSO delivery method available.

Conversion Chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule.

This design puts potency control entirely in your hands — aligning with Simpson’s principle that patients should control their medicine, but implementing it through actual product chemistry rather than rhetoric.

Our Products: Complete Transparency for Northern European Customers

RSO Sublingual Oil — $129.99

Complete Formula:

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Base: Organic MCT oil
• Volume: 30 mL (1 fl oz)
• Potency: 553 mg/mL
• Dosing: Graduated dropper with 0.1 mL increments
• Onset: 15-45 minutes (sublingual)
• Peak: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19%
• Doses per bottle: 40-60 depending on serving size

RSO Vape Cartridge — $49.99

Complete Formula:

• Live Terpenes: 5%+
• Weight: 1 gram cartridge
• Compatibility: 510-thread universal batteries
• Onset: 1-2 minutes (fastest delivery)
• Peak: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%

Terpene Profile: Sensory Experience for Northern Europeans

Our seven-terpene profile is identical across both products:

• Limonene (citrus-bright) — familiar to anyone who’s enjoyed Scandinavian cloudberry desserts or Baltic citrus preserves
• Myrcene — earthy notes reminiscent of Nordic forest floors after rain
• Caryophyllene (β-caryophyllene) — pepper/spice notes that echo the warmth of Northern European mulled wines
• Pinene (forest-fresh) — evokes the pine forests that define so much of Northern Europe’s landscape
• Linalool (floral, lavender) — connects to the lavender traditions in Swedish gardens and Finnish aromatherapy practices
• Humulene (earthy, woody) — reminiscent of Baltic saunas and traditional wooden architecture
• Terpinolene (piney, fruity, sparkling) — adds complexity that mirrors the layered flavors of Nordic cuisine

When to Use Each Format: A Guide for Northern European Lifestyles

Condition-Specific Usage Context for Northern European Patients

Important disclaimer: These contexts are informed by cannabinoid research cited in our GENERAL KNOWLEDGE section. They are not medical prescriptions, not FDA-approved treatment protocols, and not substitutes for professional medical care. Always consult a qualified healthcare provider, especially considering Northern Europe’s integrated healthcare systems. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)

Evidence context: Delta-8 THC antiemetic evidence [9], delta-9 THC nausea evidence [1][13], CBD anxiolytic buffering [3]

For Northern European context: Many cancer patients in Sweden and Norway report that medical cannabis access through their national programs is restrictive and slow. Our product offers an alternative that doesn’t require navigating bureaucratic medical cannabis applications.

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

• Daytime: 0.3-0.5 mL raw sublingual — anti-inflammatory without impairment
• Nighttime: 0.5-1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

For Northern European context: Chronic pain affects up to 20% of adults in Nordic countries. Access to pain clinics can involve long waits. Our multi-cannabinoid approach addresses inflammation through multiple pathways simultaneously — something single-molecule pharmaceuticals cannot match.

Sleep Support During Nordic Winters

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL: Delivers 50 mg CBN — the dosage investigated in 2024 sleep literature
• At 1.0 mL: Delivers 25 mg CBN — above the threshold associated with reduced sleep disturbance

Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature [17]

For Northern European context: Seasonal Affective Disorder (SAD) affects 10% of the population in northern latitudes. The combination of cannabinoids and CBN addresses both mood regulation and sleep architecture disruption caused by limited daylight.

Anxiety and Stress (Especially Relevant for High-Pressure Nordic Work Environments)

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety pathways without impairment
• Nighttime: 1.0 mL sublingual — full profile including CBN for sleep architecture

Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

For Northern European context: Nordic countries report high rates of work-related stress and burnout. The non-psychoactive raw option allows professionals to manage anxiety while maintaining performance.

General Titration Principle for Northern European Users

Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors. This conservative approach aligns with Nordic healthcare’s emphasis on safety and patient monitoring.

Delivery and Accessibility: How Northern Europeans Can Access Our Products

We operate the only same-day RSO delivery system in Houston, but for our Northern European customers, we provide comprehensive international shipping.

International Shipping to Northern Europe

We ship to all Nordic and Baltic countries where hemp-derived products with less than 0.3% delta-9 THC are permitted:

• Norway: Ships to Oslo, Bergen, Trondheim, Stavanger, and all postal codes. Customers accept customs responsibility under Norwegian regulations for hemp products.
• Sweden: Delivery to Stockholm, Gothenburg, Malmö, Uppsala, and nationwide. Full documentation provided for Swedish customs.
• Denmark: Ships to Copenhagen, Aarhus, Odense, Aalborg. COAs included for Danish customs verification.
• Finland: Delivery to Helsinki, Espoo, Tampere, Vantaa, Turku. Temperature-stable packaging for Finnish climate.
• Iceland: Ships to Reykjavík and surrounding areas. Documentation provided for Icelandic customs.
• Estonia, Latvia, Lithuania: Full shipping coverage to all Baltic capitals and regions.

What We Provide:

• Full Certificates of Analysis (COAs) for customs
• Complete product documentation and receipts
• Temperature-stable packaging for Northern European climates
• Tracking for all orders
• Discreet packaging with no cannabis branding visible
• Minimum flat-fee shipping; excessive costs billed separately

Customer Responsibility: You must verify legality in your jurisdiction and accept all customs and legal risk. Contact us at (832) 416-2816 or [email protected] with questions.

Why this matters for Northern Europe: Many of you live in countries where medical cannabis programs exist but are highly restrictive. Sweden’s program serves only a few hundred patients. Finland’s requires special licenses. Denmark’s pilot program is limited. Norway’s is similarly constrained. Our Farm Bill-compliant products provide legal access without navigating these bureaucratic barriers.

Our Evidence-Based Approach: The Science Behind Every Compound

We don’t hide behind proprietary blends. We publish complete formulas because Northern European consumers demand transparency. Here’s what the research actually says about each compound in our formula:

CBD: The Most Evidence-Developed Non-Psychoactive Cannabinoid

• Strongest evidence: Purified CBD for certain seizure disorders (FDA-approved as Epidiolex) [1][2]
• Anxiety: 2024 systematic review found statistically significant anxiolytic signal but stressed limited clinical samples [3]
• Pain: 2024 review concluded promising but heterogeneous evidence, with trial quality limiting confidence [4]
• Sleep: 2023 insomnia review found methodologically weak studies with few objective assessments [5]
• Safety: 2023 review identified liver enzyme elevation risk, especially in concentrated oral products [6]

For Northern European context: CBD is widely available across the region, but quality varies dramatically. Our 4,500 mg dose per bottle provides clinical-level concentrations far beyond typical Nordic health food store supplements.

CBG: The “Mother Cannabinoid” with Emerging Promise

• Pharmacology: Biosynthetic precursor with distinct receptor interactions (cannabinoid, alpha-2 adrenoceptors, 5-HT1A) [7]
• Research areas: Neurologic disorders, inflammatory bowel disease, antibacterial activity [7][8]
• Caution: Commercially sold despite thin evidence base [7]
• Our take: 3,000 mg inclusion makes this one of the highest-CBG products available in Northern Europe, but we present it as promising rather than proven

Delta-8 THC: The Psychoactive Cannabinoid with Real Effects

• Comparative pharmacology: 2022 review concluded similar pharmacokinetics to delta-9 THC, but less potent due to weaker CB1 affinity [9]
• Public health: 2023 scoping review found evidence dominated by animal studies and product chemistry, with reports of adverse consequences [10]
• Manufacturing: Greater stability and easier synthesis than natural plant levels [11]
• Our take: 6,000 mg makes this a significant psychoactive component. Northern European users should understand this is not “mild THC” — it’s pharmacologically active with incomplete safety characterization

THCa: The Precursor with Non-Psychoactive Potential

• Key fact: THCa itself doesn’t produce psychoactive effects [12]
• Research: Anti-inflammatory, immunomodulatory, neuroprotective, antineoplastic possibilities in preclinical models [12]
• Chemistry: Converts to THC with heating or over time during storage [12]
• Our take: 1,500 mg preserved as distinct ingredient gives Northern European users the choice between non-psychoactive raw use or full activation

Delta-9 THC: The Most Studied Psychoactive Cannabinoid

• Institutional support: NCCIH identifies relevance for chemotherapy nausea, HIV/AIDS appetite, some pain and MS outcomes [1]
• Pain evidence: 2022 systematic review found high-THC products may provide short-term pain benefit but increase dizziness, sedation, nausea [13]
• Mental health risk: 2025 systematic review found consistent unfavorable associations with psychosis and cannabis use disorder [15]
• Our take: Only 90 mg total (3 mg/mL) — dramatically lower than traditional RSO’s 600-900 mg/day. We include it for therapeutic relevance but minimize dose-related safety liabilities

CBN: The “Sleep Cannabinoid” with Weak Evidence

• Marketing vs. reality: Reputation as sleep aid far ahead of data [16][17]
• 2021 review: Screened 99 human-study abstracts, found no clinical trials using validated sleep measures [16]
• Our take: 750 mg (25 mg/mL at typical 1 mL dose) aligns with researched dosage levels, but we present it honestly: evidence is emerging, not established

CBC: The Neurogenic Cannabinoid

• Pharmacology: Distinct receptor behavior, antinociceptive, antibacterial, anti-seizure potential [18]
• Research status: Animal and in vitro evidence for anti-inflammatory effects, but not yet strong evidence for patient claims [19]
• Our take: 750 mg inclusion supports neurogenesis hypothesis, but we acknowledge this is preclinical, not clinically validated

Terpenes: Aromatic Complexity with Plausible Bioactivity

Our seven-terpene profile (5% concentration) includes:

• Limonene: Multifunctional monoterpene with antioxidant, anti-inflammatory potential [21]. Note: Oxidation products are contact allergens [22]
• Myrcene: Anxiolytic, anti-inflammatory, analgesic in preclinical models, but human evidence lacking [23]
• Caryophyllene: Selective CB2 receptor agonist — unique terpene with direct cannabinoid-system relevance [24]
• Pinene: Antioxidant, anti-inflammatory, neuroprotective signals, but limited human trials [25]
• Linalool: Stress and mood pharmacology plausible, but robust human trials lacking [22][25][26]
• Humulene: Anti-inflammatory evidence via CB1 and adenosine A2a pathways [27]
• Terpinolene: Broad biological effects in preclinical models, but clinical evidence especially underdeveloped [28]

Entourage effect reality check: The 2024 comprehensive review concluded that robust proof of clinically meaningful entourage effects in humans remains limited [20][29]. We include terpenes for plausible bioactivity and sensory experience, not as proven therapeutic actives.

Media Recognition: Why ABC13 Houston Validated Our Approach

Between 2019 and 2023, ABC13 Houston — America’s fourth-largest city’s number-one news source — featured Colin and OilWell in seven comprehensive segments. Five different reporters sought us out. No other Houston cannabis operator matches this frequency or breadth.

Why This Matters for Northern Europe: Mainstream media validation from a major-market ABC affiliate establishes credibility that transcends geography. When Nordic news outlets cover cannabis (which they rarely do), they often lack access to operators with this level of sustained, transparent media engagement.

The Seven Features:

1. September 2019: “Texas CBD businesses booming” — Our first feature, establishing the foundational philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot.”

2. March 2021: “Entrepreneur creates direct-to-consumer business” — Showed our ecosystem-building approach, helping other entrepreneurs enter legal cannabis.

3. May 2021: “What is Delta 8 THC” — Steve Campion’s investigation featured our iconic exchange: “Maybe you want to get high.” Radical honesty on mainstream TV.

4. August 2021: “Houston CBD shop giving away free products for COVID vaccine” — We donated ~$35,000 in product (1,000 caviar pre-rolls) to encourage vaccination, coordinated with Houston city government, no political strings attached.

5. October 2021: “Texas ban over Delta 8” — When Texas classified Delta-8 as Schedule I overnight, we proactively removed all products before enforcement and warned other operators who were unknowingly shipping narcotics.

6. October 2022: “Biden marijuana pardon” — Revealed Colin’s personal marijuana conviction history, putting every previous quote in deeper context. “I would love to see people not get hurt for this anymore.”

7. April 2023: “Marijuana industry getting creative” — Framed the present as a “Renaissance” to be enjoyed now, positioning us at the industry’s frontier.

The Through-Line: These features document consistency across years, breadth of expertise, community action, personal stakes, and evolution. This recognition cannot be purchased — it can only be earned through transparency and integrity.

Open-Source Formulas: Our Commitment to Accessibility

We publish complete formulas publicly. If you cannot afford our products, you can source ingredients and make your own version. This is a direct echo of Simpson’s free-distribution ethos, adapted for the modern marketplace.

The Original Open-Source Formula: Bentley’s CBD Golden Paste

We published this recipe years before our RSO formulas:

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 tsp freshly ground black pepper
• CBD oil (dosage per pet size; consult veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously for 7-10 minutes until thick paste forms
2. Add coconut oil and pepper; stir until thoroughly mixed
3. Cool and store in refrigerator up to 2 weeks
4. Mix small amount with pet’s food 1-2x daily

This pattern — giving away the formula that saved Bentley before we gave away the human formulas — demonstrates that open-source is foundational behavior, not marketing strategy.

Practical Takeaways for Northern European Consumers

1. Our most evidence-developed actives are CBD and delta-9 THC, but even here, strong evidence is concentrated in specific indications rather than broad wellness claims.

2. Delta-8 THC is not trivial — it’s psychoactive with real pharmacologic activity but less robust safety characterization than delta-9 THC.

3. THCa meaningfully changes with processing — storage and heating convert it to THC, changing the exposure profile.

4. CBG, CBN, and CBC are scientifically credible but clinically immature compared to CBD and THC.

5. Terpene claims should be conservative — bioactivity is plausible, but robust human therapeutic proof remains limited.

Legal Compliance and Shipping to Northern Europe

Age Requirement: 21+ for purchase

THC Content: All products contain less than 0.3% delta-9 THC at point of sale — Farm Bill compliant and hemp-derived.

FDA Disclaimer: Not evaluated by FDA; not intended to diagnose, treat, cure, or prevent any disease; consult healthcare provider before use; individual results may vary.

Safety Warnings: May cause drowsiness or impairment; do not operate vehicles or machinery; consult physician if pregnant or nursing; keep out of reach of children.

Legal Responsibility: Buyer accepts responsibility to check local laws; company assumes no legal responsibility for customer’s use or decarboxylation decisions; void where prohibited.

For Northern European Customers: We provide full documentation for customs. You accept responsibility for verifying your country’s specific regulations regarding hemp-derived cannabinoid products. Some Nordic countries have stricter regulations than EU baseline. Contact us before ordering if uncertain.

How to Order in Northern Europe

Online: oilwellcbd.com

Phone: +1 (832) 416-2816 (English support; we understand Nordic accents and can work with international callers)

Email: [email protected]

Shipping: We ship to all Northern European countries where hemp products are legal. Full COAs and documentation included. Temperature-stable packaging for your climate. Tracking provided.

Payment: International credit cards accepted; cryptocurrency options for privacy-conscious Nordic customers.

Questions? We’re here. We understand that ordering cannabinoid products from the U.S. to Northern Europe involves trust. We’ve earned that trust through transparency, media validation, and ten years of formulation integrity that started when Bentley got up and walked.

The Bottom Line for Northern Europe

You live in societies that value evidence, transparency, and social welfare. You have healthcare systems that provide universal access but sometimes move slowly. You face unique health challenges from long winters, high-stress work cultures, and aging populations. You deserve cannabis education that matches your values — honest about what the science says, transparent about what it doesn’t, and committed to accessibility over profit.

Our RSO isn’t traditional Rick Simpson Oil. It’s something better: a multi-cannabinoid, terpene-rich, lab-tested, patient-controlled formulation built on a decade of real-world experience and anchored to peer-reviewed evidence. We publish everything because you deserve to know exactly what you’re putting in your body. We ship internationally because healing shouldn’t stop at borders.

If you’re a cancer patient in Norway considering integrative options, a chronic pain sufferer in Sweden tired of waiting lists, a veteran in Denmark with PTSD, or anyone in Northern Europe seeking honest cannabinoid education — this is for you.

Start here. Start informed. Start with the best possible version so you can give it a fair shot and decide if it’s right or wrong for you.

OilWell Cannabis — Houston, Texas, serving Northern Europe with integrity, transparency, and the mission that began when Bentley got up.